Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Clozapine-Induced Inflammation: What Psychiatrists Should Know? (CROSBI ID 325932)

Prilog u časopisu | Pismo uredniku | međunarodna recenzija

Šagud, Marina Clozapine-Induced Inflammation: What Psychiatrists Should Know? // Psychiatria Danubina, 34(3) (2022), 427-428

Podaci o odgovornosti

Šagud, Marina

engleski

Clozapine-Induced Inflammation: What Psychiatrists Should Know?

Clozapine continues to stand out as the most effective drug in the treatment of schizophrenia. It remains the only drug approved for the treatment-resistant schizophrenia, which, unfortunately, affects up to a quarter of people even in the early stages of this disorder (Siskind et al. 2022), and also the only antipsychotic with antisuicidal effects (Forte et al. 2021). At the same time, clozapine has a number of safety considerations, which contribute to its substantial underutilization (Gurrera et al. 2022).

No key words

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

34(3)

2022.

427-428

objavljeno

0353-5053

1849-0867

Povezanost rada

Povezane osobe